+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for Treating Hyperuricemia Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Drugs for Treating Hyperuricemia Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Drugs for Treating Hyperuricemia Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6078774
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Hyperuricemia, characterized by elevated serum uric acid levels, remains a critical health concern linked to gout, renal dysfunction, and cardiovascular complications. Its increasing prevalence has intensified the demand for effective therapeutics, prompting a surge in innovation across pharmacological classes. Traditionally managed with xanthine oxidase inhibitors and uricosuric agents, the treatment paradigm has expanded to embrace recombinant uricase enzymes, offering a novel avenue for rapid uric acid breakdown.

The complexity of hyperuricemia stems from its multifactorial etiology-genetic predisposition, lifestyle factors, and comorbid conditions such as obesity and hypertension converge to disrupt uric acid homeostasis. As a result, stakeholders across the healthcare continuum must navigate evolving clinical guidelines, regulatory landscapes, and patient expectations. In this context, understanding the mechanisms, delivery formats, and market drivers behind emerging therapies is paramount.

This executive summary synthesizes transformative shifts in the therapeutic landscape, examines policy impacts, and distills segmentation and regional insights. By equipping decision-makers with actionable intelligence, it lays the groundwork for strategic investments and optimized patient outcomes.

Transformative Shifts in Hyperuricemia Treatment

The therapeutic landscape for hyperuricemia has undergone profound transformation, fueled by scientific breakthroughs and shifting patient needs. The emergence of recombinant uricase enzymes, such as pegloticase and rasburicase, has redefined expectations for rapid uric acid reduction, particularly in refractory cases. Concurrently, next-generation xanthine oxidase inhibitors like febuxostat complement established agents such as allopurinol, offering alternative dosing regimens and safety profiles.

Moreover, the integration of personalized medicine has accelerated, with genetic markers guiding drug selection to minimize adverse events and maximize efficacy. Digital health tools now enable remote monitoring of serum uric acid levels, fostering adherence and early intervention. Supply chain resilience has also advanced through strategic partnerships that ensure stable access to prefilled syringes, vials, capsules, and tablets, even amid global disruptions.

As competition intensifies, companies are investing in extended-release formulations to enhance patient convenience and sustain therapeutic levels. Market entry strategies increasingly emphasize lifecycle management and label expansions, underscoring a shift from one-size-fits-all approaches to tailored regimens. These developments collectively signal a pivotal era in which innovative modalities and data-driven insights converge to elevate standards of care.

Cumulative Impact of New U.S. Tariffs in 2025

The implementation of new U.S. tariffs in 2025 has introduced nuanced challenges and opportunities within the hyperuricemia drug market. Tariffs on both raw materials and finished pharmaceutical products have elevated procurement costs, prompting manufacturers to reassess supply chain strategies. Consequently, companies are exploring nearshoring of active pharmaceutical ingredient production to mitigate import duties and ensure continuity of supply.

Health systems and payers are responding to increased cost pressures by negotiating value-based pricing agreements, aligning reimbursement with clinical outcomes rather than volume. This shift incentivizes the development of therapies demonstrating sustained uric acid control and reduction in gout flares. At the same time, higher input costs have spurred investment in process innovations aimed at reducing waste and improving yields during manufacturing.

Regulatory agencies have also adapted, expediting review pathways for therapies that address unmet needs exacerbated by cost-driven access challenges. Stakeholders must remain vigilant to evolving trade policies, as further adjustments could influence market entry timelines and competitive positioning. On balance, the 2025 tariff changes serve as a catalyst for supply chain optimization, value-based contracting, and strategic partnerships.

Key Segmentation Insights Across Multiple Dimensions

An in-depth segmentation of the hyperuricemia treatment market reveals diverse dimensions. Based on therapeutic class, recombinant uricase enzyme modalities encompass pegloticase and rasburicase, while uricosuric agents center on probenecid, and xanthine oxidase inhibitors include allopurinol and febuxostat. Dosage form segmentation distinguishes injectables, featuring prefilled syringes and vials, from orals, which split into capsules and tablets, with tablets further subdivided into extended-release and immediate-release forms.

Distribution channels range from hospital pharmacies that manage acute care needs to online pharmacies offering home delivery and retail pharmacies providing over-the-counter access. Drug type segmentation bifurcates branded offerings, often under patent protection, and generic equivalents that drive cost competition. Patient population considerations segment adult and pediatric cohorts, with adults further differentiated into geriatric and non-geriatric groups to address age-specific pharmacodynamics.

End-users include clinics delivering outpatient management, homecare settings enabling self-administration, and hospitals overseeing inpatient interventions. Finally, mechanism of action segmentation classifies therapies by uric acid breakdown, enhancement of uric acid excretion, and inhibition of uric acid production. Each dimension underscores the need for tailored strategies that align product portfolios with patient demographics, therapeutic preferences, and channel dynamics.

Key Regional Dynamics Shaping Market Access

Regional analysis highlights distinct drivers across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a robust pipeline and strong payer networks support rapid adoption of novel biologics, while digital health integration fosters telemonitoring programs. The diverse EMEA landscape navigates regulatory harmonization under centralized and national authorities, balancing cost containment with incentives for innovation through adaptive licensing.

Asia-Pacific exhibits accelerated growth fueled by rising disposable incomes, expanding healthcare infrastructure, and proactive public health campaigns that elevate disease awareness. Markets such as Japan and South Korea prioritize high-precision diagnostics and advanced formulations, whereas emerging economies in Southeast Asia emphasize affordable generics and local manufacturing capabilities.

Cross-regional collaborations are on the rise, with joint ventures addressing manufacturing scalability and clinical trial diversity. Real-world evidence initiatives are gaining traction globally, enabling stakeholders to benchmark treatment outcomes across populations. Understanding these regional nuances empowers strategic entrants and established players to tailor market access plans, pricing models, and distribution partnerships.

Key Company Strategies and Competitive Landscape

Leading pharmaceutical and biotech enterprises are driving innovation and market expansion. Aeqium Pharmaceuticals, LLC is advancing novel uric acid lowering agents, while Ajanta Pharma Limited leverages cost-efficient manufacturing to compete on generics. Astellas Pharma Inc. and AstraZeneca Pharmaceuticals LP focus on combination therapies and extended-release formulations, bolstering adherence.

Boehringer Ingelheim GmbH and Dr. Reddy’s Laboratories Ltd. pursue global clinical programs and biosimilar development, with GlaxoSmithKline plc exploring patient support initiatives to enhance engagement. Hikma Pharmaceuticals PLC emphasizes injectable portfolio diversification, and Horizon Therapeutics plc capitalizes on its leadership in recombinant uricase therapies. Mylan N.V. and Sun Pharmaceutical Industries Ltd. drive competitive pressure through pricing strategies in key markets.

Sanofi S.A. and Takeda Pharmaceutical Company Limited invest in pharmacogenomics to refine patient selection, while Teijin Pharma Limited explores advanced delivery systems. Zydus Cadila Healthcare Ltd. augments its footprint through regional partnerships and portfolio extensions. Collectively, these organizations illustrate a blend of innovation, cost management, and strategic alliances that shape the competitive landscape.

Actionable Recommendations for Industry Leaders

Industry leaders can capitalize on emerging trends by adopting a proactive, patient-centric approach. First, integrate pharmacogenomic profiling into clinical workflows to tailor therapy selection and minimize adverse events. Second, optimize supply chain resilience by diversifying sourcing options and leveraging regional manufacturing hubs to offset tariff impacts.

Third, develop outcome-based contracting models that align reimbursement with real-world efficacy, fostering stronger payer partnerships. Fourth, invest in digital therapeutics and remote monitoring platforms to enhance adherence and capture real-world data for continuous improvement. Fifth, pursue strategic alliances with diagnostic companies to bundle testing and treatment, creating integrated care solutions.

Additionally, prioritize lifecycle management through extended-release and combination formulations that extend patent life and address unmet patient needs. Finally, adopt a flexible market entry strategy that accounts for regional regulatory nuances and distribution channel preferences. These targeted actions will position organizations to lead in a competitive, evolving hyperuricemia market.

Conclusion and Strategic Takeaways

This comprehensive review underscores the rapid evolution of hyperuricemia therapeutics, driven by scientific innovation, regulatory shifts, and dynamic market forces. The advent of recombinant uricase enzymes complements established modalities, while personalized medicine and digital health tools enhance patient outcomes and adherence.

The impact of new tariff policies has accelerated supply chain optimization and value-based contracting, influencing global sourcing decisions. Detailed segmentation across therapeutic class, dosage form, distribution channel, drug type, patient population, end-user, and mechanism of action highlights opportunities for targeted product development and market entry strategies. Regional insights further reveal how the Americas, EMEA, and Asia-Pacific each present unique access challenges and growth prospects.

Leading companies are differentiating through innovation, cost efficiencies, and strategic partnerships. By adopting actionable recommendations-ranging from pharmacogenomics to digital integration-stakeholders can navigate competitive pressures and regulatory landscapes effectively. Ultimately, this synthesis equips decision-makers with the clarity and direction required to advance patient care and achieve sustainable growth.

Market Segmentation & Coverage

This research report categorizes the Drugs for Treating Hyperuricemia Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Recombinant Uricase Enzyme
    • Pegloticase
    • Rasburicase
  • Uricosuric Agents
    • Probenecid
  • Xanthine Oxidase Inhibitors
    • Allopurinol
    • Febuxostat
  • Injectable
    • Prefilled Syringes
    • Vials
  • Oral
    • Capsules
    • Tablets
      • Extended Release
      • Immediate Release
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Branded
  • Generic
  • Adult Patients
    • Geriatric
    • Non-Geriatric
  • Pediatric Patients
  • Clinics
  • Homecare Settings
  • Hospitals
  • Enhancement of Uric Acid Excretion
  • Inhibition of Uric Acid Production
  • Uric Acid Breakdown

This research report categorizes the Drugs for Treating Hyperuricemia Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Drugs for Treating Hyperuricemia Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Aeqium Pharmaceuticals, LLC
  • Ajanta Pharma Limited
  • Astellas Pharma Inc.
  • AstraZeneca Pharmaceuticals LP
  • Boehringer Ingelheim GmbH
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Horizon Therapeutics plc
  • Mylan N.V.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Zydus Cadila Healthcare Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs for Treating Hyperuricemia Market, by Therapeutic Class
8.1. Introduction
8.2. Recombinant Uricase Enzyme
8.2.1. Pegloticase
8.2.2. Rasburicase
8.3. Uricosuric Agents
8.3.1. Probenecid
8.4. Xanthine Oxidase Inhibitors
8.4.1. Allopurinol
8.4.2. Febuxostat
9. Drugs for Treating Hyperuricemia Market, by Dosage Form
9.1. Introduction
9.2. Injectable
9.2.1. Prefilled Syringes
9.2.2. Vials
9.3. Oral
9.3.1. Capsules
9.3.2. Tablets
9.3.2.1. Extended Release
9.3.2.2. Immediate Release
10. Drugs for Treating Hyperuricemia Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Drugs for Treating Hyperuricemia Market, by Drug Type
11.1. Introduction
11.2. Branded
11.3. Generic
12. Drugs for Treating Hyperuricemia Market, by Patient Population
12.1. Introduction
12.2. Adult Patients
12.2.1. Geriatric
12.2.2. Non-Geriatric
12.3. Pediatric Patients
13. Drugs for Treating Hyperuricemia Market, by End-User
13.1. Introduction
13.2. Clinics
13.3. Homecare Settings
13.4. Hospitals
14. Drugs for Treating Hyperuricemia Market, by Mechanism of Action
14.1. Introduction
14.2. Enhancement of Uric Acid Excretion
14.3. Inhibition of Uric Acid Production
14.4. Uric Acid Breakdown
15. Americas Drugs for Treating Hyperuricemia Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Drugs for Treating Hyperuricemia Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Drugs for Treating Hyperuricemia Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Aeqium Pharmaceuticals, LLC
18.3.2. Ajanta Pharma Limited
18.3.3. Astellas Pharma Inc.
18.3.4. AstraZeneca Pharmaceuticals LP
18.3.5. Boehringer Ingelheim GmbH
18.3.6. Dr. Reddy's Laboratories Ltd.
18.3.7. GlaxoSmithKline plc
18.3.8. Hikma Pharmaceuticals PLC
18.3.9. Horizon Therapeutics plc
18.3.10. Mylan N.V.
18.3.11. Sanofi S.A.
18.3.12. Sun Pharmaceutical Industries Ltd.
18.3.13. Takeda Pharmaceutical Company Limited
18.3.14. Teijin Pharma Limited
18.3.15. Zydus Cadila Healthcare Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. DRUGS FOR TREATING HYPERURICEMIA MARKET MULTI-CURRENCY
FIGURE 2. DRUGS FOR TREATING HYPERURICEMIA MARKET MULTI-LANGUAGE
FIGURE 3. DRUGS FOR TREATING HYPERURICEMIA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. DRUGS FOR TREATING HYPERURICEMIA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. DRUGS FOR TREATING HYPERURICEMIA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUGS FOR TREATING HYPERURICEMIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PROBENECID, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY NON-GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ENHANCEMENT OF URIC ACID EXCRETION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INHIBITION OF URIC ACID PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URIC ACID BREAKDOWN, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 95. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 96. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 97. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 99. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 100. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 101. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 102. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 105. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 106. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 108. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 110. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 113. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 114. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 115. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 119. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 166. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 167. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 168. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 169. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 171. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 172. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 173. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 174. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 177. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 178. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 180. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 181. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 182. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 183. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 185. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 186. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 187. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 188. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 190. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 191. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 192. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 194. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 195. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 197. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 209. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 210. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 211. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 213. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 214. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 215. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 216. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 219. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 220. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 222. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 223. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 225. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 227. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 228. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 229. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 236. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 237. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 238. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 239. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 241. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 242. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 243. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 250. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 251. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 252. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 253. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 255. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 256. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 265. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 278. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 279. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 280. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 281. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 283. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 284. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 285. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 286. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 288. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 289. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 290. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. TAIWAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 292. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 293. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE ENZYME, 2018-2030 (USD MILLION)
TABLE 294. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 295. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 296. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 297. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 298. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 299. THAILAND DRUGS

Companies Mentioned

  • Aeqium Pharmaceuticals, LLC
  • Ajanta Pharma Limited
  • Astellas Pharma Inc.
  • AstraZeneca Pharmaceuticals LP
  • Boehringer Ingelheim GmbH
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Horizon Therapeutics plc
  • Mylan N.V.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Zydus Cadila Healthcare Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Hyperuricemia - Pipeline Insight, 2025 - Product Image

Hyperuricemia - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Hyperuricemia Drugs Market Report 2025 - Product Image

Hyperuricemia Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 188 Pages
  • Global
From
Hyperuricemia - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Hyperuricemia - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Elitek or Fasturtec Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Elitek or Fasturtec Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.